

Haematologica
HAEMATOL/2019/220012
Version 3

A phase 1 trial of alisertib and romidepsin for relapsed/refractory
aggressive B-cell and T-cell lymphomas

Paolo Strati, Loretta J. Nastoupil, Richard E. Davis, Luis E. Fayad,
Nathan Fowler, Fredrick B. Hagemeister, Larry Kwak, Yasuhiro Oki,
Michael Wang, Jason Westin, Charnelle E. Ruben, Emily T. Wesson,
Richard Piekarz, Michelle A. Fanale, and Hun Ju Lee

Disclosures: NCI-CTEP U01 Grant Program at MDACC, Celgene, Millennium/Takeda, and
National Stem Cell Foundation

Contributions: MAF designed the study, analyzed the data, provided clinical care to
patients, and wrote the paper; PS analyzed data and wrote the paper; RP designed the
study and coauthored the paper; LEF, LN, RED, NF, FH, LK, HL, YO, MW and JW
provided clinical care to patients and coauthored the paper; ETW and CER collected the
data and coauthored the paper.